EMBED - DK, FR, ES, Se example page - Larta - Report - Page 26
THE QUICK COMMERCIAL EXIT, AVALON BIOMED
ACQUIRED BY NUSMILE
THE INITIAL PUBLIC OFFERING, PULSE BIOSCIENCES
NOVEMBER 2016
$20M
IPO WITH ADDITIONAL GROSS
PROCEEDS OF OVER $3M
COMMERCIAL EXIT ACHIEVED
Women-Owned Business
Acquired by NuSmile in 2016
Industry: Life Sciences/Healthcare
Technology: Bioactive dental cements
that save teeth from extraction
Larta Program: NIH CAP 2014-2015
FIRST DERMATOLOGICAL
IN 5 YEARS
ACHIEVED PROFITABILITY,
Industry: Life Sciences/Healthcare
Technology: NPES: Nano Pulse Electro
Signaling to treat tumors
Larta Program: NIH CAP 2006-2007,
Venture Forum 2007
STARTING FROM NIH SBIR
“I fully credit Larta’s CAP program with the fact
that my sales went up by a factor of 10. Larta
helped me realize my company’s value. I was
able to turn that understanding into forward
motion, which led to our acquisition by NuSmile.”
CAROLYN PRIMUS, PRESIDENT, AVALON BIOMED
Q+A:
Carolyn Primus
President, Avalon Biomed
What is your company’s technology?
Children needed a product to save traumatized teeth from extraction. We developed
and manufactured bioactive materials to induce healing of the tooth pulp, which
helps save children's teeth.
What sets your company apart from the competition?
Our product is specifically for children. Available products on the market were not
as effective and turn teeth gray. Ours is more effective, competitively priced, and
does not turn teeth gray to ensure healthy teeth from youth to continue to adulthood.
What was Larta’s impact on your company?
I fully credit Larta’s CAP program with the fact that my sales went up by a factor
of 10. Larta helped me realize my company's value. I was able to turn that understanding into forward motion, which led to our acquisition by NuSmile.
23
COMPANY PROFILES
GRANT AND LARTA NIH CAP
MARKETED PRODUCTS IN 10
COUNTRIES AROUND THE
WORLD
HUMAN PILOT STUDY WITH
PULSETX SYSTEM
PRESENTED RESULTS OF
THREE PRECLINICAL STUDIES AT
“Larta taught me how to protect my innovation,
negotiate a license to use pulse generators on
tumors, and shepherd my company to where
we are today: closing a $23 million IPO.”
RICHARD NUCCITELLI, CSO, PULSE BIOSCIENCES
SOCIETY FOR IMMUNOTHERAPY OF CANCER
“THE PURSUIT OF AN IPO IS
EXTREMELY RARE, ESPECIALLY
THIS EARLY IN A COMPANY’S
DEVELOPMENT. PULSE BIO-
“THROUGH LARTA’S NIH CAP,
CAROLYN BUILT A PROFITABLE
COMPANY, ESTABLISHED
MANUFACTURING IN THE U.S.,
AND RELEASED A PREMIUM,
COST-EFFECTIVE PRODUCT
SOLD WORLDWIDE. MOST
OF ALL, SHE ACHIEVED A
COMMERCIAL EXIT IN JUST
FIVE SHORT YEARS.”
LOU SCARMOUTZOS
LARTA PRINCIPAL ADVISOR
Q+A:
Richard Nuccitelli
CSO, Pulse Biosciences
What is your company’s technology?
Our Nano-Pulse Electro Signaling (NPES) device changes the way we treat cancer.
Our method triggers specific cell death in cancerous tissue without harming
healthy tissue and activates the patient’s immune system, inhibiting growth of
new cancerous tissue.
What sets your company apart from the competition?
There is no other technology like ours on the market. Current cancer treatments are
non-specific with severe side effects and risk of relapse. Because our technology
uses the patient's natural apoptosis (cell death process) to eliminate the cancer, there
are no adverse side effects.
What was Larta’s impact on your company?
I started out as an innovator, but after completing the Larta CAP program,
I would define myself as an entrepreneur.
SCIENCES IS A TRUE SUCCESS
STORY DUE TO LARTA’S COMMERCIALIZATION ACCELERATOR
PROGRAMS.”
JOHN VASSILIADES
PRINCIPAL ADVISOR